On October 20, 2021 F. Hoffmann-La Roche Ltd. (hereafter "Roche") [Head Office: Basel, Switzerland. CEO: Severin Schwan] reported its third quarter sales 2021 (January 1 – September 30, 2021) (Press release, Chugai, OCT 20, 2021, View Source [SID1234591568]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roche owns 59.89% of Chugai’s outstanding shares (61.16% of the total number of shares issued excluding treasury stock) as of the end of September 2021.

Its investor updates and presentation materials can be found on its website (View Source).
Chugai’s performance for the period of January 1 to September 30, 2021 is included in the announced Roche Group’s results.

On October 20, 2021 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") reported that the company has ranked first in the pharmaceuticals sector for the "2021 Award for Excellence in Corporate Disclosure" granted by the Securities Analysts Association of Japan (SAAJ) to promote the quality and fairness of corporate disclosure (Press release, Astellas, OCT 20, 2021, View Source [SID1234591566]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Astellas was highly evaluated mainly in the following areas:

Significant improvement in IR stance, with the top management’s proactive information dissemination and engagement in dialogue
IR group has sufficient accumulated information, and securities analysts and institutional investors are having a useful dialogue with IR personnel
Announcement of a medium-term plan ("Corporate Strategic Plan 2021" *1), a full explanation of subsequent progress with concrete measures for achievement, and a capital allocation policy
Stock market needs are incorporated into the disclosure materials of the medium-term plan
Astellas’ raison d’être is "to contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products." With research and development at the heart of the company, Astellas constantly takes on challenges to deliver innovative new drugs and medical solutions by leveraging its core capabilities. In addition, Astellas aims to sustainably enhance its enterprise value by being chosen and trusted by all the stakeholders including customers, shareholders, employees and community.

Upon receiving the award, Kenji Yasukawa, President and CEO, Astellas, stated as follows:
"Our disclosure philosophy is to make our products on the market and the clinical trial results known in a timely and appropriate manner, as well as proactively explain to the stakeholders not only the features of the projects under research and development, but also the potential impact on society when they are launched. In addition, we strive to make the opportunity to provide information flexibly in line with the requests and needs of the stakeholders so that we do not unilaterally disseminate information. As a result of these efforts, we believe that we were able to improve the perception of our advocacy activities and our disclosure philosophy, which led to this recognition."

Astellas will continue to disclose information in a timely, appropriate, and fair manner, as well as proactively engage in dialogue with stakeholders and further improve transparency. Astellas will continue to strive to enhance and improve the quality of its disclosure.

On October 19, 2021 /PRNewswire/ — PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, reported that the patent for PMC-309, one of the Company’s first immuno-oncology assets, has been granted by IP Australia, the Australian government agency that administers intellectual property rights (Press release, PharmAbcine, OCT 19, 2021, View Source;bmode=view&idx=8574626&t=board [SID1234649186]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Australian grant represents PMC-309’s third global patent approval since it received grants from Russia in June 2021 and South Korea in July 2021. The Company also plans to get more patents approved in other countries, including the U.S, Canada, China, Japan, European nations, and etc.

PMC-309 is a first-in-class antibody that antagonizes VISTA (V-domain Ig Suppressor of T cell Activation) and is in development to treat various tumor types. VISTA plays a pivotal role in maintaining the immunosuppressive environment around the tumor cells and is expressed primarily on immunosuppressive cells, such as MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells). Blocking VISTA pathways on immunosuppressive cells promotes T cells’ immune responses and leads to better anti-tumor effects.

According to the nonclinical data of PMC-309 presented at AACR (Free AACR Whitepaper) (American Association for Cancer Research) 2021, PMC-309 showed promising anti-tumor effects comparable to an existing anti-PD-1 drug. However, when used in combo with an anti-PD-1 drug, PMC-309 demonstrated significantly improved tumor growth inhibitions than either mono therapies.

In April 2021, PharmAbcine initiated IND-enabling studies of PMC-309. The studies are required to establish the safety profile in animals before entering the human trial. The Company expects to enter a Phase I global trial in 2022.

"This patent grant is one of the key milestones that underlines our approach to help patients with unmet medical needs with a novel first-in-class antibody candidate and builds stronger intellectual property position in the immuno-oncology field," said Dr. Jin-San Yoo, CEO of PharmAbcine. "Our team believes that PMC-309, with its unique mode of action that does not overlap with the existing drugs, will be a new treatment option in both mono and combo therapies for patients who do not respond well to the current immunotherapies."

On October 19, 2021 Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, reported that Company CEO, Eyal Barad, will present at the upcoming Edison Open Forum: Cannabinoids 2021, taking place today, Wednesday, October 19th (Press release, Cannabics Pharmaceuticals, OCT 19, 2021, View Source [SID1234592177]). Mr. Barad’s talk will focus on the pharmaceutical development of synthetic cannabinoid-based drug candidates for colorectal cancer and other cancers designated for FDA regulatory review.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Eyal Barad, Cannabics Pharmaceuticals Co-Founder and CEO said: "We are proud to have been selected to present at Edison’s Open Forum Conference and share our perspective on synthetic cannabinoid drug development and on the challenges, opportunities and trends we see in the industry."

To access the Forum and the presentation please register at the following link:

View Source

On October 19, 2021 Aadi Bioscience, Inc. ("Aadi"), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at H.C. Wainwright’s 2nd Annual Precision Oncology Conference, which will be held virtually (Press release, Aadi Bioscience, OCT 19, 2021, View Source [SID1234592016]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Information:

Date: Wednesday, October 20, 2021

Time: 1 pm ET

To Listen to the Presentation:

The live webcast can be accessed here: View Source A replay will also be available at this link for 90 days and posted on Aadi’s website within the Investors & News/Events & Presentations section.